PubMed

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T.

Diabetes Care. 2003 Sep;26(9):2581-7.PMID: 12941722 [PubMed - indexed for MEDLINE]Related articlesFree article

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabet Med. 2001 Feb;18(2):144-9.PMID: 11251679 [PubMed - indexed for MEDLINE]Related articles

Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.

Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D.

Diabetes Care. 2003 Oct;26(10):2835-41.PMID: 14514588 [PubMed - indexed for MEDLINE]Related articlesFree article

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ.

Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.

Diabetes Care. 1998 Nov;21(11):1925-31.PMID: 9802745 [PubMed - indexed for MEDLINE]Related articlesFree article

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.

Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B.

Diabetes Care. 1997 Dec;20(12):1874-9.PMID: 9405910 [PubMed - indexed for MEDLINE]Related articles

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article

Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.

Vilsbøll T, Agersø H, Krarup T, Holst JJ.

J Clin Endocrinol Metab. 2003 Jan;88(1):220-4.PMID: 12519856 [PubMed - indexed for MEDLINE]Related articlesFree article

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.PMID: 12189441 [PubMed - indexed for MEDLINE]Related articles

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.

J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903.PMID: 14557471 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.

Diabetes Care. 2000 Jun;23(6):807-12.PMID: 10841001 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

Diabetologia. 1996 Dec;39(12):1546-53.PMID: 8960841 [PubMed - indexed for MEDLINE]Related articles

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.

Diabetes Care. 2003 Mar;26(3):791-8.PMID: 12610039 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.

Diabet Med. 1998 Nov;15(11):937-45.PMID: 9827848 [PubMed - indexed for MEDLINE]Related articles

Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.

Gutniak MK, Linde B, Holst JJ, Efendić S.

Diabetes Care. 1994 Sep;17(9):1039-44.PMID: 7988303 [PubMed - indexed for MEDLINE]Related articles

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

Diabetes Care. 1996 Jun;19(6):580-6.PMID: 8725855 [PubMed - indexed for MEDLINE]Related articles

Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA.

Exp Clin Endocrinol Diabetes. 1998;106(2):103-7.PMID: 9628239 [PubMed - indexed for MEDLINE]Related articles

Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.

Zander M, Christiansen A, Madsbad S, Holst JJ.

Diabetes Care. 2004 Aug;27(8):1910-4.PMID: 15277416 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of glucagon-like peptide 1(7-36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis.

Hedetoft C, Sheikh SP, Larsen S, Holst JJ.

Pancreas. 2000 Jan;20(1):25-31.PMID: 10630380 [PubMed - indexed for MEDLINE]Related articles

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.

Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.

Clin Sci (Lond). 1998 Sep;95(3):325-9.PMID: 9730852 [PubMed - indexed for MEDLINE]Related articles